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Juzentaihoto (JTT) is well known to be one of Japanese herbal medicines, and used for the supplemental therapy of cancer
patients with remarkable success. The present study, therefore, was undertaken to examine the possible therapeutic mechanisms
of JTT on cancer using B16 melanoma cell (B16 cell)/experimental mouse system. JTT was well mixed with rodent chow at
3.0% concentrations, and was administered orally ad libitum. Administration of JTT was started one week before tumor cell
injection and continued throughout the experiment. Administration of JTT into mice signiﬁcantly inhibited tumor metastasis
in lungs after intravenous injection of 2 × 105 B16 cells in a volume of 50μL. JTT also signiﬁcantly suppressed enlargement of
tumor size in hind footpad after the subcutaneous injection of 2 × 105 (50μL) B16 cells. In the second part of experiments,
the chamber that containing B16 cells was buried in the murine back. In JTT administrated group, vascular endothelial growth
factor (VEGF) of chamber internal ﬂuid signiﬁcantly decreased, and vascularization of chamber circumference was also inhibited.
These results strongly suggest that oral administration of JTT caused decrease in the generation of VEGF, which is responsible for
vascularization, and results in inhibition of B16 cell metastasis.
1.Introduction
Cancer patients generally undergo surgical therapy, chemo-
therapy, radiotherapy, or a combination of these treatments.
Whiletheeﬀectsofthesetreatmentsaresigniﬁcant,itisafact
that most patients suﬀer from side eﬀects, such as high fever,
general fatigue, loss of appetite, pancytopenia, and many
kinds of infections.
In Japan and China, herbal medicines, including Juzen-
taihoto (JTT), Hochuekkito, and among others, are used as
a supplemental therapy for many kinds of chronic diseases
such as loss of appetite, anemia, and chilliness of the arms
a n dl e g sw i t hr e m a r k a b l es u c c e s s[ 1, 2]. Recent reports
clearly showed that when herbal medicines are used for
cancer treatment, many patients experience fewer or di-
minished side eﬀects induced by western medicine, such as
chemotherapy and radiotherapy, and the survival period
is longer [3, 4]. It is also reported that herbal medicine
can prevent the progression of colon carcinoma, gastric
and breast cancer as well as the prevention of these cancer
metastasis to the liver, lung, and bone [3, 4]; moreover,
hepatocellular carcinoma has been shown to become smaller
without severe side eﬀects after the treatment with herbal
medicine [5]. Although these reports strongly suggest that
herbal medicines will be a good candidate for the treatment
of several types of cancer, the mechanisms by which herbal
medicines could improve clinical status, including cancer
metastasis, of cancer patients.
Angiogenesis is involved early in tumor progression as
well as in sustained growth, invasion of established tumors,
and the development of metastasis [6]. The regulation of
angiogenesis is closely related to speciﬁc angiogenic factors
and their receptors [7]. The predominant angiogenic factor
is vascular endothelial growth factor (VEGF), a glycoprotein
stimulating mitosis of endothelial cells and their migra-
tion [7]. Moreover, VEGF increases capillary permeability
responsible for cancer metastases [7–9].
Our previous work clearly showed that oral administra-
tionofJTTfor21daysinhibitedmetastasisofB16melanoma
cells (B16 cell) on lung surfaces through the enhancement2 Evidence-Based Complementary and Alternative Medicine
of NK-cell activities. However, the inﬂuence of JTT on
angiogenesis was not clear at present [10].
In this study, we examined the eﬀects of JTT on the
vascularization of B16 cell, as well as its eﬀects on the VEGF
production in B16 cells.
2.MaterialsandMethods
2.1. Animals. Speciﬁc pathogen-free C57BL/6 male mice,
6-week-old, were purchased from Japan CLEA Co., Ltd.
(Tokyo, Japan). The animals were maintained at 25 ± 2◦C,
humidity 50 ± 2%, and a light and dark cycle of 12 hours
in our animal facilities. They were randomly divided into
groups of 10 mice and fed chow containing 3% JTT [11]o r
regular diet (control). This study was approved by the Ethics
Committee of Showa University for animal experiments (no.
01067).
2.2.PreparationofDietContainingJTT. JTTwasprovidedby
Tumura Co. Ltd. (Tokyo, Japan) as a preservative-free pure
powder (Table 1). JTT was well-mixed with regular powder
diet (CE-2) for maintaining rats and mice (Japan Clea Co.
Ltd., Tokyo, Japan) at concentrations of 3.0% [11].
2.3. Cell Line (Tumor Cells). B16 cells, a highly metastatic
mice cell line, were purchased from Dai-Nippon Pharma-
ceutical Co. Ltd. (Osaka, Japan) and maintained with RPMI-
1640 medium supplemented with 10% heat-inactivated fetal
calf serum (FCS: Flow Laboratories, North Ride, Australia),
100 units/mL penicillin, 100μg/mL streptomycin, at 37◦Ci n
5% CO2 atmosphere.
2.4. Assay for Tumor Cell Metastasis. In the ﬁrst experiments,
B16 cells (2 × 105 cells) were injected intravenously into
recipient mice in a volume of 50μL. After 21 days, mice
were killed under ether anesthesia and the number of tumor
colonies on the lung surface was counted under a dissecting
microscope (SZ-60; OLYMPUS Co. Ltd., Tokyo, Japan).
In the second experiments, B16 cells (2 × 105 cells) were
injected subcutaneously into the left hind pad in a volume
of 50μL. After 21 days, the tumor was removed in the knee
under a dissecting microscope (OLYMPUS Co. Ltd., Tokyo,
Japan). The volume of tumor lumps (cutting departments)
was measured by a water displacement method, using a
plethysmometer (model no. TK-101P; Muromachi kikai,
Tokyo, Japan) [12]. These mice were then maintained for
further 21 days and the black dots, showing tumor colony
formation on the lung surface, were counted under a
dissecting microscope (OLYMPUS Co. Ltd.). In these two
experiments, mice were given food-containing JTT and tap
water ad libitum for two or three weeks starting 7 days before
tumor cell injection.
2.5. Assay for Cytotoxic Activity of JTT. B16 cells (5 × 105
cells) were introduced into each well of 24 well culture plates
that contained 10% and 25% serum prepared from mice
treated with JTT for 21 days in triplicate. After 24 hours,
the numbers of viable cells were counted with a Countess
Automated Cell Counter (Invitrogen Co., Tokyo, Japan) in
the presence of trypan blue.
2.6. Millipore Chamber (MPC) Implantation. Millipore Cha-
mbers (MPCs) [13, 14] containing B16 cells (1 × 106 cells)
were implanted into the diﬀerent experimental groups. The
componentsofaMPCconsistedofaplasticholdingchamber
(Millpore UK Ltd., Watford, UK), two ﬁxation discs, and
two 0.45μm pore size Millipore Filters of 14mm diameter
(Millipore UK Ltd.). B16 cells cultured were placed in
the holding chambers which were then closed by sealing
a Millipore Filter at both ends using the ﬁxation discs.
Recipient mice were anaesthetized using an intraperitoneal
sodium pentobarbital. A dorsal longitudinal incision was
made and a subcutaneous plane developed into which was
inserted a chamber containing B16 cells, and the incision
closed with a subcutaneous suture.
2.7. Assay for VEGF Production from B16 Cells. VEGF
level in culture supernatants and the MPCs internal ﬂuid
was examined using commercially available mouse VEGF
enzyme-linked immunosorbent assay (ELISA) kits (R&D
Systems, Inc., Minneapolis, Minn, USA) according to the
manufacturer’s recommendations. The sensitivity of VEGF
assay kit was 3pg/mL.
2.8.DeterminationoftheEﬀectofJTTonInVivoAngiogenesis.
Angiogenesis was induced by implantation of the MPCs
containingB16cells(1×106 cells/animal)hypodermicallyon
the shaven dorsum skin mouse [15]. After 21 days of MPCs
implantation, all animals were sacriﬁced and B16 cells and
body ﬂuid in the chamber were collected. At the same time,
the skin adhering to the chamber and blood were collected.
The body ﬂuid and serum were used for the estimation
of VEGF using ELISA kits according to the manufacturer’s
recommendation. Dorsum skins removed were washed with
PBS and the length of tumor-directed blood vessels per
cm2 around the tumor was measured using a dissecting
microscope (OLYMPUS Co. Ltd.) [16] .T h ei m a g e so f
mouse hypodermis were magniﬁed to 250 diameters, and
the blood vessels length using Digital Scale (FS-DSC101;
Firestar Co. Ltd., Hiroshima, Japan) were measured. In
addition, these skins were dipped in 4% formalin and used
for immunohistological staining [14].
2.9. Immunohistochemistry for Angiogenesis. The experimen-
tal and control skins were stained with the rat primary
antibody for mouse CD31 (PECAM-1; BD Biosciences,
Tokyo, Japan) to examine the presence of the neogenesis
blood vessels in the hypodermis [17, 18]. The shin tissues
were washed several times with saline to remove unwanted
materials (e.g., blood and connective tissues, etc.), ﬁxed
in 4% paraformaldehyde-PBS, followed by 5%, 15%, and
30% sucrose-PBS; specimens were then embedded in Tissue-
Tek (Sakura Finetechnical Co. Ltd., Tokyo, Japan) and
cut into 10μm sections. These sections were treated with
3% hydrogen peroxide in PBS to eliminate endogenous
peroxidase activity and treated with blocking buﬀer (PBSEvidence-Based Complementary and Alternative Medicine 3
Table 1: Botanical origins of ten crude drugs of JTT from the 2006 Japanese Pharmacopoeia.
Crude drugs Scientiﬁc name of botanical origin Ratio
Astragali Radix Astragalus membranaceus Bunge or A. mongholicus Bunge 3.0
Cinnamomi Cortex Cinnamomum cassia Blume or other species of the same genus 3.0
Rehmanniae Radix Rehamannia glutinosa Liboschitz var. Purpurea Makino or A. glutinosa Liboschitz 3.0
Paeoniae Radix Paeonia lactiﬂora Pallas or allied plants 3.0
Cnidii Rhizoma Cnidium oﬃcinale Makino 3.0
Atractylodis Lanceae Rhizoma Atractylodes lancea De Candolle or A. chinesis Koidzumi 3.0
Angelicae Radix Radix Angelica acutiloba Kitagawa or allied plants 3.0
Ginseng Radix Panax ginseng C. A. Meyer 3.0
Hoelen The sclerotium of Poria cocos Wolf 3.0
Glycyrrhizae Radix Glycyrrhiza uralensis Fisch, G. grabra Linne, or other species of the same genus 1.5
containing 5% normal rat serum) for 30min. Sections were
thenincubatedwithCD31at4◦Cfor12hours.Afterwashing
withPBS,thesectionswerefurtherincubatedwithsecondary
antibodies (Histoﬁne Simple Stain Mouse MAX-PO (Rat)
kit;Nichirei,Tokyo,Japan)for30min.Afterthreerinseswith
PBS, the sections were incubated with diaminobenzidine
substrate (Research Genetics, Huntsville, Ala, USA) for 1
to 2min. The sections were rinsed with distilled water
and counterstained with methyl green. After processing of
dehydration with ethanol, the samples were observed under
a microscope (BM-2; OLYMPUS Co. Ltd., Tokyo, Japan).
2.10. Preparation of JTT-Pulsed Serum and Cell Culture.
The mice were given diet containing JTT and tap water ad
libitum for 21 days. Blood samples were obtained by cardiac
puncture and separated the serum. B16 cells (2 × 104 cells)
were grown in 100μL of PRMI-1640 medium supplemented
with 10% heat-inactivated mice serum in a 96-well plate in
triplicate. After 24 hours, B16 cells and supernatant were
collectedandusedforthemeasurementofmRNAexpression
forVEGFbyreal-timePCRintriplicate andproteinofVEGF
by ELISA in triplicate.
2.11. PCR Primers and Reagent Kits. The reagents used
for mRNA isolation (TaqMan Gene Expression Cells-to-Ct)
and real-time RT-PCR (TaqMan Gene Expression Assays)
were purchased from Applied Biosystems (Foster City,
Calif, USA). These assays were performed according to
the manufacturer’s instructions [19]. For real-time RT-PCR
comparison of gene expression, we selected VEGF gene (vas-
cular endothelial growth factor A: TaqMan Gene Expression
Assays; Assay ID: Mm01281449 m1) related to vasculariza-
tion. GAPDH, glyceraldehydes-3-phosphate dehydrogenase,
was used as a housekeeping gene to normalize for RNA
loading.
2.12. mRNA Isolation: Quantitative RT-PCR. Total RNA
was isolated from B16 cells using 50μLL y s i sS o l u t i o n
(P/N4383583). Each sample of total RNA was subjected to
reverse transcription (RT) using 20 × RT Enzyme Mix (P/N
4383585) and 2 × RT Buﬀer (P/N43833586) with Applied
Biosystems2720 ThermalCycler(Applied Biosystems,Foster
City, Calif, USA). After the RT reaction, the cDNA templates
were ampliﬁed by polymerase chain reaction using TaqMan
Gene Expression Assays, PCR primers, and RT master Mix
(P/N 4369016). Predesigned and validated gene-speciﬁc
TaqMan Gene Expression Assays [19, 20]f r o mA p p l i e d
Biosystem were used in duplicate for quantitative RT-PCR
according to the manufacturer’s protocol. PCR assays were
used with the following protocol: 10min denaturation at
95◦C, and 40 cycles of 15s denaturation at 95◦C, 1min
annealing and extension at 60◦C .S a m p l e sw e r ea n a l y z e d
using an ABI Prism 7900HT Fast Real-Time PCR System
(Applied Biosystems) [20, 21]. Relative quantiﬁcation (RQ)
studies [22] were made from collected data (threshold
cycle numbers, referred to as Ct) with ABI Prism 7900HT
Sequence-Detection System (SDS) software 2.3 (Applied
Biosystem).
2.13. Statistical Analysis. Continuous variables were pre-
sented as the mean ± standard error of the mean SEM.
The statistical signiﬁcance between the control and the
experimental groups was analyzed with analysis of variance
followed by Fisher’s protested least signiﬁcant diﬀerence
test. A P value of less than 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Suppression of B16 Melanoma Cell Metastasis by JTT.
This experiment was undertaken to examine the inﬂuence
of oral administration of JTT on tumor cell metastasis
using diﬀerent two types of experimental models. Mice
pretreated with 3.0% JTT were injected intravenously with
2 × 105 B16 cells and were killed 21 days later to count
the number of tumor cell colonies on the lung surfaces.
As shown in Figure 1(a), oral administration of 3.0% JTT
could cause signiﬁcant suppression of B16 cell metastasis.
We then examined whether oral administration of JTT could
also prevent spontaneous tumor cell metastasis as in the case
of intravenous administration of tumor cells. As shown in
Figure 1(b), administration of 3.0% JTT into mice could
prevent spontaneous B16 cell metastasis from right hind
footpad to lung surfaces.4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Inﬂuence of Juzentaihoto (JTT) on B16 melanoma cell metastasis in mice. C57BL/6 mice were orally administered JTT, which was
startedoneweekbeforeinjectionof2×105 melanomacellsandkilled3or6weekslatertocounttumorcellcoloniesinthelungs.(a)Number
of colonies in the lungs 3 weeks after intravenous injection of cells; (b) number of tumor colonies in the lungs 6 weeks after subcutaneous
injection of cells. ∗P<0.05 versus control (each group: n = 10, mean ± SEM).
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Figure 2: Inﬂuence of JTT on tumor cell growth in vitro or in vivo. JTT administration animal exerts cytotoxic eﬀects on B16 melanoma
cells and results in the prevention of tumor cell metastasis. (a) Eﬀect of JTT on paw swelling. ∗P<0.05 versus control. (b) Eﬀect of the
serum principle of JTT administration animals on B16 cultured cells (each group: n = 10, mean ± SEM).Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀect of JTT on angiogenesis (MPCs). The ability of JTT to inhibit in vivo tumor-induced angiogenesis was examined by
implantation of the MPCs containing B16 cells (1 × 106 cells/animal) hypodermically intradermally on the shaven dorsum of animals.
In the sham group, the vascularization occurred mildly. (a) The blood vessels images which were induced by B16-MPCs. (b) Neogenesis
vascular length which was induced by B16-MPCs. ∗P<0.05 (each group: n = 10, mean ± SEM).
3.2. Eﬀect of JTT on Paw Swelling. This experiment was
undertaken to examine the inﬂuence of oral administration
of JTT on paw swelling caused by tumor cell growth. Tumor
cell growth of mice treated with 3.0% JTT were injected
into the palm with 2 × 105 B16 cells and the volume of the
palm was measured after 21 days. As shown in Figure 2(a),
oral administration of 3.0% JTT could cause signiﬁcant
suppression of paw swelling owing to the tumor growth.
3.3. Eﬀect of Serum Obtained from JTT-Treated Mouse
on B16 Cell Viability. The present study was designed to
determine whether the serum prepared from mice treated
with JTT exerts cytotoxic eﬀects on B16 cells and results
in the prevention of tumor cell metastasis. B16 cells at a
concentration of 5 × 105 cells/well were cultured in the
mouse serum for 24 hours and the numbers of viable cells
were counted with trypan blue dye exclusion test. As shown
inFigure 2(b), JTTgroupcouldnot suppressB16cellgrowth
even when cells were cultured in the presence of 25% mice
serum: the number of cells in experimental cultures is almost
equal (not signiﬁcant; P>0.05) to that observed in control
cultures.
3.4. Eﬀect of JTT on Angiogenesis. The ability of JTT to
inhibit in vivo tumor-induced angiogenesis was examined
by implantation of the MPCs containing B16 cells (1 ×6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: CD31 is expressed on neogenesis blood vessels. Comparison of CD31 expression patterns (brown) with each experimental groups.
“a–c” are high magniﬁcation of “A–C”. (A–C) Scale bars, 250μm. (a–c) Arrows are the staining parts of cd31. Scale bars, 50μm.
106 cells/animal) hypodermically on the shaven dorsum of
animals. In the sham group, the vascularization occurred
mildly. In the group that implanted B16-MPCs, the blood
vessels, which were induced by the tumor, were signiﬁcantly
r e d u c e di nt h eJ T T - t r e a t e dg r o u p( Figure 3(a)). Control
animals had the length of 10427.0 ± 1641.7μm/cm2 around
the MPCs whereas JTT-treated animals had mere 6711.3 ±
345.4μm/cm2 (Figure 3(b)).
3.5. Immunohistochemistry for CD31. Antiangiogenesis is a
major anticancer mechanism. Therefore, the skins of MPCs
contact hypodermis were evaluated in sections stained with
CD31 to further investigate the antiangiogenic eﬀect of JTT.
As shown in Figure 4, the (a–c) were high magniﬁcation
photographs of (A–C), the neogenesis blood vessels (CD31-
positive) of the control groups had increased as compared
with the sham groups (the CD31-positive cells were shown
in arrows). In contrast, vascularization was decreased in the
JTT-treated groups.
3.6.InﬂuenceofJTTonVEGFProductionfromB16Cells. The
experiment was undertaken to examine the inﬂuence of JTT
on VEGF production from B16 cells. The VEGF contents
in culture supernatants and the MPCs internal ﬂuid were
examined by ELISA. As shown in Figure 5(a), JTT in culture
supernatants suppressed the ability of B16 cells to produce
VEGF. In addition, as shown in Figure 5(b), JTT treatment
in the MPCs internal ﬂuid suppressed the ability of B16 cells
to produce VEGF.
3.7. Eﬀect of JTT on the VEGF mRNA Expression. The
ﬁnal experiment was carried out to examine whether oral
administration of JTT could cause decrease in VEGF mRNA
expression of the B16 cells. As shown in Figure 6, in the B16
cells contained in the MPCs, the VEGF mRNA expression
of the JTT treatment groups had decreased signiﬁcantly as
compared with the control groups.
4. Discussion
Herbalmedicineisusedfrequentlyasasupplementaltherapy
for many kinds of chronic diseases with remarkable success
[1]. In cases of treatment for cancer, herbal medicine is
reported to be able to prevent the progression of colon
carcinoma,gastricandbreastcanceraswellastheprevention
of the cancer metastasis to the liver, lung, and bone [23].
However, the precise mechanisms by which herbal medicine
can alleviate the clinical symptoms of cancer patients such
as tumor metastasis, are not well deﬁned. The present
study, therefore, was undertaken to examine the possible
therapeutic mechanisms of herbal medicine on cancer
through the choice of JTT and B16 cell/mouse system inEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: Inﬂuence of JTT on VEGF production from B16 cell. The experiment was undertaken to examine the inﬂuence of JTT on VEGF
production from B16 cells. (a) The VEGF level contents in culture supernatants. (b) The VEGF level contents in the MPCs internal ﬂuid.
∗P<0.05 versus control (each sample: n = 10, mean ± SEM).
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Figure 6: Eﬀect of JTT on the VEGF mRNA expression. The experiment was carried out to examine whether oral administration of JTT
could cause decrease in VEGF mRNA expression of theB16 cells. (a)The VEGF mRNA expression of B16culture cells. (b) TheVEGF mRNA
expression of the B16 cells contained in the MPCs. ∗P<0.05 versus control (each sample: n = 10, mean ± SEM).
vivo and in vitro. The present results clearly showed that oral
administration of JTT inhibited B16-cell colony formation
on the lung surface, when the recipient mice were given
tumor cells intravenously (Figure 1(a)). JTT also suppressed
spontaneous B16 tumor cell metastasis from hind footpad
to the lung surface (Figure 1(b)). The prevention of tumor
cell growth and metastasis is well accepted to be through
diverse mechanisms, including tumor cell death, apoptosis,
and immune-mediated cancer regression. Our results clearly
showed the absence of cytotoxic eﬀects of JTT on B16 cells
(Figure 2(b)). It is also showed that oral administration
of JTT suppressed the paw swelling by B16 cell growth,8 Evidence-Based Complementary and Alternative Medicine
suggesting that neovascularized mechanisms to promote
metastasis are responsible for the prevention of tumor cell
colony formation on the lung surface.
In the next study, we focused on the role of JTT during
the initial growth phase in the spontaneous metastasis of
B16 cells; tumor-induced neovascularization and tumor
growth. In the present study, we observed the decrease of
neovascularization on tumor tissues treated by JTT adminis-
tration, especially in the MPCs implanted mice (Figures 3(a)
and 3(b)). The experiments of the MPCs implanted B16
cells clearly demonstrate that the high density of CD31-
positive vessels in the site of dorsal skin is detectable by
immunohistochemical staining. The endothelial cell pro-
liferation (CD31 positive cells) was also inhibited by oral
JTT administration. It is important to know about the
antiangiogenic eﬀect with JTT administration, because good
candidates for antiangiogenic drugs include those available
for oral administration for a long term without severe
systemic side eﬀects [24]. JTT has satisﬁed these conditions
and could be a candidate for an antiangiogenic material for
patients with cancer.
Angiogenesis is composed of several processes: disso-
ciation of pericytes from preexisting vessels, digestion of
extracellular matrix with proteases, proliferation, migration
and invasion of endothelial cells, and tube formation, and
then ﬁnally remodeling occurs. VEGF is considered to
be secreted from tumor cells in a paracrine fashion to
induce blood vessel growth. Even though VEGF is a potent
mitogenic stimulation of endothelial cells, several studies
have demonstrated the ability of VEGF to function as a
survival factor for endothelial cells [25]. Since VEGF is
generated from a variety of tumors, it is the most important
angiogenic factor associated closely with induction and
maintenance of the neovasculature in human tumors [26,
27]. We observed the decrease in VEGF levels in the MPCs
contents and culture supernatants treated by JTT (Figure 5).
In addition, JTT decreased VEGF mRNA expression in B16
cells (Figure 6) prepared from mice pretreated with JTT
for 21 days, but did not culture B16 cells with JTT-treated
mouse serum. The reasons for this discrepancy in in vitro
experiments are not dear at present. The process of protein
synthesis requires two diﬀerent steps. In the ﬁrst step, so-
called transcription, mRNA is synthetized from DNA in the
nucleus. mRNA formed then comes out through nuclear
membrane into cytoplasm where it attaches to mRNA-
binding site on ribosome and starts protein synthesis which
is called translocation step. Therefore, there is a possibility
that short-term (within 24h) exposure of B16 cells with
metabolized JTT in vitro could inhibit only translocation
step. Further experiments are needed to clarify this point.
These antiangiogenic activities of oral JTT administration
may be responsible for the prevention of B16 tumor cell
metastasis.
We reported that oral administration of JTT into mice
caused B16 cell metastasis through the enhancement of IFN-
γ functions [10]. It is also showed that VEGF-A secre-
tion from corneal ﬁbroblasts induced by proinﬂammatory
cytokine (e.g., TNF-α and IL-1) stimulation was suppressed
by IFN-γ [28]. Taken together, it is suggested that JTT may
possess novel pharmacologic properties that interfere with
angiogenesis triggered by VEGF secreted from B16 primary
oncocytes through the enhancement of IFN-γ mechanism.
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